琥珀酸他舒格替尼的用法用量

Tasugatinib succinate is a targeted drug used to treat specific types of biliary tract cancer. This article will introduce in detail the standard usage and dosage, recommended course of medication, and contraindications for use of this drug. Understanding these contents can help patients regulate their medication use and minimize the risk of adverse reactions while obtaining the best therapeutic effect.

Dosage and dosage of tasugatinib succinate

The dosage regimen needs to be accurately adjusted according to the individual patient's condition to ensure the safety and effectiveness of the treatment.

Standard dosage regimen

The recommended dose for adult patients is 140 mg once daily. It is recommended to take it on an empty stomach to optimize drug absorption. This drug is a 35 mg/tablet film-coated tablet, and patients need to accurately calculate the number of tablets to take according to the doctor’s instructions.

Principles of dose adjustment

When adverse reactions occur, a stepwise reduction is required: from 140 mg to 105 mg, then to 70 mg, and finally to 35 mg. Serious adverse reactions may require temporary discontinuation of treatment or permanent discontinuation of treatment, and specific adjustments need to be determined based on the type and severity of the adverse reactions.

Dosing Precautions

The tablet should be swallowed whole and should not be chewed or crushed. If you miss a dose, take it as soon as you remember, but not close to the time of your next dose to avoid double doses. You should maintain adequate fluid intake while taking the medication.

Patients should strictly follow the usage and dosage specifications of tasugatinib succinate.

The treatment course of tasugatinib succinate

The treatment cycle of this drug needs to be individualized according to the patient's condition changes and tolerance.

Duration of treatment

Treatment should be continued until disease progression or intolerable toxicity occurs. Clinical data shows that some patients can continue to take the medication for several months or even longer, and the specific course of treatment varies from person to person.

Effectiveness evaluation cycle

It is recommended to conduct a comprehensive efficacy evaluation every 8-12 weeks, including imaging examinations and tumor marker testing. At the same time, adverse reactions need to be monitored regularly and treatment plans adjusted in a timely manner.

Long-term medication management

Patients taking long-term medication need to establish a standardized follow-up plan, focusing on chronic toxicities such as hyperphosphatemia and eye lesions. Intermittent dosing may be considered if necessary to reduce adverse reactions.

Scientific and reasonable medication schedule can help patients achieve the best balance between efficacy and safety.

Contraindications of tasugatinib succinate

Understanding the contraindications of this drug is important to prevent serious adverse consequences.

Absolute contraindications

This drug is contraindicated in pregnant women because of its embryo-fetal toxicity. Patients with severe liver function impairment (total bilirubin >1.5×ULN) should also avoid use, as it may cause drug accumulation and poisoning.

Relative contraindications

Lactating women should stop breastfeeding if they need to take medication. Patients of childbearing potential need to take strict contraceptive measures. Patients with severe renal insufficiency should use it with caution as sufficient safety data are lacking.

Patients with active ocular disease should be evaluated for benefit-risk ratios. It is prohibited for those who are allergic to drug ingredients. Patients taking concomitantly strong CYP3A inhibitors need to be closely monitored for adverse reactions.